Developmental Therapeutics for Myelodysplastic Syndromes

The management strategy for patients with myelodysplastic syndromes (MDS) has evolved from sole reliance on supportive measures to active treatment guided by disease risks. Recent progress in understanding the molecular pathogenesis of MDS has accelerated the discovery of new therapeutic targets, and consequently launched the development of several novel therapeutics that are currently in varied stages of clinical testing. One such agent is lenalidomide, which has shown remarkable effectiveness in the cytogenetically defined subset of MDS with the chromosome 5q31 deletion. The advent of new and effective targeted therapeutics may beneficially affect outcomes of an ever-increasing number of patients with MDS. This discussion summarizes the preliminary results of selected novel therapeutics.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Alan List, MD, Chief, Division of Malignant Hematology, 12902 Magnolia Drive, SRB-4, Tampa, FL 33612-9497. E-mail: listaf@moffitt.usf.edu
  • 1.

    VardimanJWHarissNLBrunningRD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood2002;100:2229222302.

    • Search Google Scholar
    • Export Citation
  • 2.

    GreenbergPCoxCLe BeauM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood1997;89:20792088.

  • 3.

    ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:96719674.

    • Search Google Scholar
    • Export Citation
  • 4.

    JonasovaANeuwirtovaRCermakJ. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br J Haematol1998;100:304309.

    • Search Google Scholar
    • Export Citation
  • 5.

    MolldremJJLeiferEBaheciE. Antithymocyte globulin for treatment of bone marrow failure associated with myelodysplastic syndrome. Ann Intern Med2002;137:156163.

    • Search Google Scholar
    • Export Citation
  • 6.

    MolldremJJCaplesMMavroudisD. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol1997;99:699705.

  • 7.

    BarrettAJMolldremJJSaunthrajarianY. Prolonged transfusion independence and disease stability in patients with myelodysplastic syndrome responding to antithymocyte globulin [abstract]. Blood1998;92:713.

    • Search Google Scholar
    • Export Citation
  • 8.

    SaunthararajahYNakamuraRWesleyR. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood2003;102:30253027.

    • Search Google Scholar
    • Export Citation
  • 9.

    GersukGMLeeJWBeckhamCA. Fas (CD95) receptor and fas ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood1998;88:11221123.

    • Search Google Scholar
    • Export Citation
  • 10.

    StasiRAmadoriS. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes [abstract]. Br J Haematol2002;116:334.

    • Search Google Scholar
    • Export Citation
  • 11.

    RazaAQaviHLisakL. Patients with myelodysplastic syndrome benefit from palliative therapy with amifostine, pentoxyfylline, and ciprofloxacin with or without dexamethasone. Blood2000;95:580587.

    • Search Google Scholar
    • Export Citation
  • 12.

    GrossiAMustoPSantiniV. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndrome. Haematologica2002;87:322323.

    • Search Google Scholar
    • Export Citation
  • 13.

    BellamyWTRichterLSirjaniD. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood2001;97:14271434.

    • Search Google Scholar
    • Export Citation
  • 14.

    RazaAMeyerPDuttD. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood2001;98:958965.

    • Search Google Scholar
    • Export Citation
  • 15.

    Moreno-AspitiaAGeyerSLiC. N998B: multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS) [abstract]. Blood2002;100:96.

    • Search Google Scholar
    • Export Citation
  • 16.

    ListAKurtinSRoeDJ. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med2005;352:549557.

  • 17.

    ListADewaldGBennettJ. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J Clin Oncol2005;23:2S.

    • Search Google Scholar
    • Export Citation
  • 18.

    ListAFSchillerGJMasonJ. Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase II clinical study [abstract]. Blood2003;102:423.

    • Search Google Scholar
    • Export Citation
  • 19.

    RazaALisakLATahirS. Trilineage responses to arsenic trioxide (Trisenox®) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2) [abstract]. Blood2002;100:795.

    • Search Google Scholar
    • Export Citation
  • 20.

    VeyNDreyfusFGuerciA. Trisenox (arsenic trioxide) in patients (pts) with myelodysplastic syndromes (MDS): preliminary results of a phase 1/2 study [abstract]. Presented at the 8th Congress of the European Hematology Association; June 12-152003; Lyon, France.

    • Search Google Scholar
    • Export Citation
  • 21.

    GotlibJJamiesonCListA. Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS) [abstract]. Blood2003;102:425.

    • Search Google Scholar
    • Export Citation
  • 22.

    ForanJPaquetteRCopperM. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed or are not eligible for conventional chemotherapy [abstract]. Blood2002;100:558.

    • Search Google Scholar
    • Export Citation
  • 23.

    GilesFSteinfeldtHBellamyWT. Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome [abstract]. Blood2004;104:502.

    • Search Google Scholar
    • Export Citation
  • 24.

    ReuterCWMMorganMABergmannL. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Blood2000;96:16551669.

    • Search Google Scholar
    • Export Citation
  • 25.

    GolubTBarkerGLovettMGillilandD. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell1994;77:307316.

    • Search Google Scholar
    • Export Citation
  • 26.

    ApperleyJFGardembasMMeloJV. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med2002;347:481487.

    • Search Google Scholar
    • Export Citation
  • 27.

    NikasSNDrososAA. SFCIO-469 Scios Inc.Curr Opin Investig Drugs2004;5:12051212.

  • 28.

    ReuterCWMMorganMABergmannL. Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Blood2000;96:16551669.

    • Search Google Scholar
    • Export Citation
  • 29.

    KurzrockRKantarjianHMCortesJ. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood2003;102:45274534.

    • Search Google Scholar
    • Export Citation
  • 30.

    KurzrockRAlbitarMCortesJE. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol2004;22:12871292.

    • Search Google Scholar
    • Export Citation
  • 31.

    FeldmanEJCortesJHolyoakeT. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood2003;102:421.

    • Search Google Scholar
    • Export Citation
  • 32.

    BureshAPerentesisJRimszaL. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia2005;19:308310.

    • Search Google Scholar
    • Export Citation
  • 33.

    CallanderNOchoa-BayonaJLPiroL. Hematologic improvement following treatment with TLK199 (Telintra™), a novel glutathione analog inhibitor of GST P1-1, in myelodysplastic syndrome (MDS): interim results of a dose-ranging phase 2a study [abstract]. Blood2004;104:1428.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 40 40 4
PDF Downloads 7 7 0
EPUB Downloads 0 0 0